

November 18, 2024

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai - 400001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra –Kurla Complex, Bandra (E),
Mumbai - 400051

Dear Sir(s),

**Subject: Launch of Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+
Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri
Aerosphere)**

We refer to our earlier communication dated December 2, 2023, intimating the receipt of Import and Market Permission in Form CT-20 from the Drugs Controller General of India for Budesonide Ph. Eur 160mcg+ Glycopyrronium Ph. Eur 7.2mcg+ Formoterol Fumarate Dihydrate Ph. Eur 5mcg inhalation preparations (Breztri Aerosphere).

With regard to the same, we wish to further update that AstraZeneca Pharma India Limited will launch Breztri Aerosphere in January 2025 in India.

Breztri Aerosphere is indicated for the maintenance treatment to relieve symptoms and prevent exacerbations in adult patients with chronic obstructive pulmonary disease (COPD).

We request you to kindly take the above on records.

Thanking You,

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary